• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC14D9C filed by Day One Biopharmaceuticals Inc.

    3/6/26 8:56:42 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DAWN alert in real time by email
    SC14D9C 1 d321704dsc14d9c.htm SC14D9C SC14D9C
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14D-9

    (Rule 14d-101)

    Solicitation/Recommendation Statement

    under Section 14(d)(4) of the Securities Exchange Act of 1934

     

     

    Day One Biopharmaceuticals, Inc.

    (Name of Subject Company)

     

     

    Day One Biopharmaceuticals, Inc.

    (Name of Person(s) Filing Statement)

     

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    23954D 109

    (CUSIP Number of Class of Securities)

    Jeremy Bender

    Chief Executive Officer and President

    Day One Biopharmaceuticals, Inc.

    1800 Sierra Point Parkway, Suite 200

    Brisbane, CA 94005

    Telephone: (650)-484-0899

    (Name, address and telephone number of person authorized to receive notice and communications

    on behalf of the persons filing statement)

     

     

    With copies to:

     

    Effie Toshav, Esq.

    Douglas N. Cogen, Esq.

    Robert A Freedman, Esq.

    Julia Forbess, Esq.

    Fenwick & West LLP

    555 California Street, 12th Floor

    San Francisco, CA 94104

    (415) 875-2300

     

    Charles N. York II

    Chief Operating Officer and Chief Financial Officer

    Day One Biopharmaceuticals, Inc.

    1800 Sierra Point Parkway, Suite 200

    Brisbane, CA 94005

    (650)-484-0899

     

     

     

    ☒

    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

     

     
     


    This Schedule 14D-9 filing consists of the following communications related to the proposed acquisition of Day One Biopharmaceuticals, Inc., a Delaware corporation (the “Company” or “Day One”), by Servier S.A.S., a French société par actions simplifiée (“Servier”), Servier Pharmaceuticals LLC, a Delaware limited liability company and an indirect wholly owned subsidiary of Servier (“Parent”), and Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub” and together with Servier and Parent, the “Servier Parties”), pursuant to the terms of the Agreement and Plan of Merger dated March 6, 2026, by and among the Company, Servier, Parent and Merger Sub (the “Merger Agreement”):

     

      •  

    Joint Press Release, dated March 6, 2026 (Exhibit 99.1).

     

      •  

    Employee FAQ sent to the Company’s employees, dated March  6, 2026 (Exhibit 99.2).

     

      •  

    Email sent to the Company’s stakeholders, dated March  6, 2026 (Exhibit 99.3).

     

      •  

    Email sent to the Company’s employees, dated March  6, 2026 (Exhibit 99.4).

     

      •  

    Company social media post, dated March 6, 2026 (Exhibit 99.5).

    Cautionary Notice Regarding Forward-Looking Statements

    This communication contains forward-looking statements relating to the proposed acquisition of Day One by the Servier Parties. These forward-looking statements are not based on historical fact and include statements regarding the ability of Day One and the Servier Parties to complete the transactions contemplated by the Merger Agreement, including the parties’ ability to satisfy the conditions to the consummation of the tender offer (the “offer”) contemplated thereby and the other conditions set forth in the Merger Agreement, statements about the expected timetable for completing the transaction, Day One and Servier’s beliefs and expectations and statements about the benefits sought to be achieved by the Servier Parties’ proposed acquisition of Day One, the potential effects of the acquisition on both Day One and Servier, and the possibility of any termination of the Merger Agreement. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “intend,” and other similar expressions, among others. These forward-looking statements are based on current assumptions that involve risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to future events and trends that Day One believes may affect the financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs of Day One. There can be no guarantee that such expectations and projections will prove accurate in the future.

    All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Actual results may differ materially from current expectations because of risks associated with uncertainties as to the timing of the offer and the subsequent merger; uncertainties as to how many of Day One’s stockholders will tender their shares in the offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the merger and the offer contemplated thereby may not be satisfied or waived; the effects of disruption from the transactions contemplated by the Merger Agreement on Day One’s business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; and the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability. Moreover, Day One operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. Although Day One believes that the expectations reflected in such forward-looking statements are reasonable, it cannot guarantee future events, results, actions, levels of activity, performance or achievements, business and market conditions, the timing and results of any developments and whether the conditions to the closing of the proposed acquisition are satisfied on the expected timetable or at all. Other risks that may affect the future results of Day One and the Servier Parties are identified in their respective filings with the Securities and Exchange Commission (the “SEC”) or other public disclosures. These forward-looking statements speak only as of the date they are made, and Day One and the Servier Parties undertake no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.


    Additional Information about the Acquisition and Where to Find It

    The offer referenced in this communication has not yet commenced. This communication is for informational purposes only, is not a recommendation and is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that the Servier Parties will file with the SEC upon commencement of the offer. A solicitation and offer to buy outstanding shares of Day One will only be made pursuant to the tender offer materials that the Servier Parties intend to file with the SEC. At the time the offer is commenced, the Servier Parties will file with the SEC tender offer materials on Schedule TO, and Day One will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer.

    THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF DAY ONE ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME), BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF DAY ONE SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal) will be made available to all stockholders of Day One at no expense to them under the “Investor Resources” section of Day One’s website at https://ir.dayonebio.com/ or by email at [email protected], or by directing requests for such materials to the information agent for the offer, which will be named in the tender offer materials, and (once they become available) the tender offer materials as well as the Solicitation/Recommendation Statement will be mailed to the stockholders of Day One free of charge. Copies of the documents filed with the SEC by Day One will be available free of charge on Day One’s website, https://ir.dayonebio.com/, or by contacting Day One’s investor relations department at [email protected]. The information contained in, or that can be accessed through, Day One’s website is not a part of or incorporated by reference herein. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Day One files annual, quarterly, and current reports, proxy statements, and other information with the SEC. You may read any reports, statements, or other information filed by Servier or Day One with the SEC for free on the SEC’s website at www.sec.gov.

    Get the next $DAWN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DAWN

    DatePrice TargetRatingAnalyst
    1/13/2026$34.00Buy
    TD Cowen
    8/19/2025$25.00Overweight
    Piper Sandler
    10/9/2024$32.00 → $33.00Buy
    Needham
    8/1/2024$11.00 → $24.00Underperform → Buy
    BofA Securities
    4/24/2024$30.00 → $33.00Buy
    Needham
    4/25/2023$34.00 → $9.00Buy → Underperform
    BofA Securities
    2/8/2023$40.00Overweight
    CapitalOne
    2/3/2023Perform
    Oppenheimer
    More analyst ratings

    $DAWN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ai Day1 Llc bought $14,978,327 worth of shares (1,475,454 units at $10.15) (SEC Form 4)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    10/20/23 4:02:31 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    SEC Filings

    View All

    SEC Form SC TO-C filed by Day One Biopharmaceuticals Inc.

    SC TO-C - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    3/6/26 8:59:32 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC14D9C filed by Day One Biopharmaceuticals Inc.

    SC14D9C - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    3/6/26 8:56:42 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Day One Biopharmaceuticals Inc.

    8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

    3/6/26 8:52:47 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

    Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs. Transaction represents total equity value of approximately $2.5 billion.SURESNES, France and BRISBANE, Calif., March 6, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acquire Day One f

    3/6/26 10:21:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio

    Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric cancers with high unmet needs Transaction represents total equity value of approximately $2.5 billion SURESNES, France and BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that they have entered into a definitive agreement for Servier to acq

    3/6/26 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

    OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today reports its finan

    2/24/26 4:00:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen resumed coverage on Day One Biopharmaceuticals with a new price target

    TD Cowen resumed coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $34.00

    1/13/26 8:59:51 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Day One Biopharmaceuticals with a new price target

    Piper Sandler initiated coverage of Day One Biopharmaceuticals with a rating of Overweight and set a new price target of $25.00

    8/19/25 8:33:40 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham reiterated coverage on Day One Biopharmaceuticals with a new price target

    Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $32.00 previously

    10/9/24 7:46:01 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    April 30, 2024 - FDA Roundup: April 30, 2024

    For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/30/24 3:20:20 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 26, 2024 - FDA Roundup: April 26, 2024

    For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

    4/26/24 3:10:22 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

    Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

    4/24/24 12:52:43 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Merendino Lauren converted options into 15,162 shares and sold $67,448 worth of shares (5,814 units at $11.60), increasing direct ownership by 18% to 60,157 units (SEC Form 4)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    2/18/26 5:18:49 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gen Counsel & Secretary Dubow Adam converted options into 16,463 shares and sold $74,188 worth of shares (6,395 units at $11.60), increasing direct ownership by 16% to 72,694 units (SEC Form 4)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    2/18/26 5:17:40 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO and CFO York Charles N Ii converted options into 23,375 shares and sold $70,359 worth of shares (6,065 units at $11.60), increasing direct ownership by 6% to 312,025 units (SEC Form 4)

    4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

    2/18/26 5:16:10 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Leadership Updates

    Live Leadership Updates

    View All

    Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

    Dr. Michael Vasconcelles brings more than 25 years of extensive oncology research, development and health technology expertise and corporate executive leadership to Day One Dr. Vasconcelles to drive pipeline creation and execution BRISBANE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research & Development (R&D). "We are thrilled to welcome Mike during this pivotal time at Day One. As an

    6/10/25 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

    Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of R&D. "Sam's passion for pediatric oncology

    11/20/24 4:30:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One Announces Two New Appointments to Board of Directors

    BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointments of Habib Dable and Dr. William Grossman to its Board of Directors. "We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth," said Jeremy Bender, Ph.D., chief executive officer of Day One. "Their deep expertise and leadership in oncology will further strengthen our Board and will be a great asset as we prepare for the potential launch of ou

    1/17/24 8:00:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Financials

    Live finance-specific insights

    View All

    Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

    OJEMDA™ 2025 momentum reflected by Q4 and full year net product revenues of $52.8 million and $155.4 million, respectively 2026 U.S. net product revenue projected at $225 - $250 million Expanded pipeline with January 2026 acquisition of Mersana Therapeutics; Emi-Le in Phase 1 trial for adenoid cystic carcinoma (ACC) Day One to host conference call and webcast today, February 24, 4:30 p.m. ET BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today reports its finan

    2/24/26 4:00:00 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

    BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2025. Live audio of the webcast will be accessible by visiting the Events section of Day One's Media & Investors page. An archived version of the webcast will be available for replay in the Events section for 30 days follo

    2/10/26 8:30:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases

    Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid cystic carcinoma type-1 (ACC-1), a cancer with high unmet need and a lack of therapeutic options Day One will apply existing scientific and commercial capabilities to this investigational innovative therapeutic with a clear potential registration path Company to host conference call and webcast today, November 13, 8:00 am Eastern Time BRISBANE, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company

    11/13/25 6:00:00 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DAWN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

    SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/14/24 4:30:11 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

    SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/7/24 9:24:55 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Day One Biopharmaceuticals Inc.

    SC 13G - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

    11/7/24 9:12:22 AM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care